Bellerophon Therapeutics Past Earnings Performance
Past criteria checks 0/6
Bellerophon Therapeutics's earnings have been declining at an average annual rate of -5.6%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 103.6% per year.
Key information
-5.6%
Earnings growth rate
88.9%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 103.6% |
Return on equity | -220.5% |
Net Margin | -219.9% |
Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Bellerophon Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 6 | -12 | 7 | 13 |
31 Mar 23 | 6 | -11 | 6 | 15 |
31 Dec 22 | 0 | -20 | 6 | 16 |
30 Sep 22 | 0 | -19 | 6 | 16 |
30 Jun 22 | 0 | -19 | 6 | 15 |
31 Mar 22 | 0 | -18 | 6 | 14 |
31 Dec 21 | 0 | -18 | 7 | 13 |
30 Sep 21 | 0 | -21 | 8 | 13 |
30 Jun 21 | 0 | -25 | 8 | 14 |
31 Mar 21 | 0 | -25 | 9 | 14 |
31 Dec 20 | 0 | -25 | 8 | 18 |
30 Sep 20 | 0 | -21 | 8 | 12 |
30 Jun 20 | 0 | -17 | 7 | 11 |
31 Mar 20 | 0 | -17 | 6 | 11 |
31 Dec 19 | 0 | -13 | 6 | 11 |
30 Sep 19 | 0 | -10 | 7 | 11 |
30 Jun 19 | 0 | 5 | 7 | 13 |
31 Mar 19 | 0 | -2 | 8 | 16 |
31 Dec 18 | 0 | 3 | 8 | 20 |
30 Sep 18 | 0 | -20 | 8 | 22 |
30 Jun 18 | 0 | -39 | 9 | 21 |
31 Mar 18 | 0 | -32 | 8 | 20 |
31 Dec 17 | 0 | -55 | 7 | 18 |
30 Sep 17 | 0 | -38 | 8 | 17 |
30 Jun 17 | 0 | -35 | 8 | 15 |
31 Mar 17 | 0 | -36 | 8 | 14 |
31 Dec 16 | 0 | -24 | 8 | 16 |
30 Sep 16 | 0 | -27 | 6 | 20 |
30 Jun 16 | 0 | -34 | 9 | 24 |
31 Mar 16 | 0 | -41 | 11 | 29 |
31 Dec 15 | 0 | -46 | 15 | 33 |
30 Sep 15 | 0 | -48 | 16 | 35 |
30 Jun 15 | 0 | -53 | 15 | 39 |
31 Mar 15 | 0 | -58 | 16 | 43 |
31 Dec 14 | 0 | -60 | 14 | 46 |
30 Sep 14 | 0 | -64 | 13 | 50 |
31 Mar 14 | 0 | -62 | 10 | 53 |
31 Dec 13 | 0 | -62 | 9 | 53 |
Quality Earnings: 6L7A is currently unprofitable.
Growing Profit Margin: 6L7A is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6L7A is unprofitable, and losses have increased over the past 5 years at a rate of 5.6% per year.
Accelerating Growth: Unable to compare 6L7A's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6L7A is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: 6L7A has a negative Return on Equity (-220.54%), as it is currently unprofitable.